Breast Cancer Update Nurses 1 | 2007

You are here: Home: Audio Program Guide: BCU Nurses 1 | 2007 Audio: BCU Nurses 1 | 2007


	Go to interview with Dianne D Chapman, ND, RN, ANP Go to interview with Hope S Rugo, MD Go to interview with Mark D Pegram, MD Go to interview with Harold J Burstein, MD, PhD Go to interview with Stephen E Jones, MD


	To listen to individual tracks now, click on the track you wish to listen to. To download tracks, right-click on the one you wish to download.


	Dianne D Chapman, ND, RN, ANP Nurse Practitioner, Comprehensive Breast Center/RISC Program Division of Hematology and Oncology Rush University Medical Center Chicago, Illinois
	Click here to download the entire interview

Track 1

Introduction

Track 2

Nurse’s personal experience with breast cancer

Track 3

Psychological issues faced by women with breast cancer

Track 4

Coping with a diagnosis of breast cancer

Track 5

Helping patients cope with the side effects of therapy

Track 6

Utility of the Oncotype DX™ assay in clinical practice


	Hope S Rugo, MD Clinical Professor of Medicine Carol Franc Buck Breast Care Center Co-director, Breast Oncology Clinical Trials Program University of California, San Francisco Comprehensive Cancer Center San Francisco, California
	Click here to download the entire interview

Track 1

Introduction

Track 2

Mechanism of action of anti-angiogenic agents

Track 3

Clinical trials of bevacizumab in the metastatic and adjuvant settings

Track 4

Combination of bevacizumab with chemotherapy and potential toxicities

Track 5

Clinical responses with bevacizumab

Track 6

Selection of an agent in taxane therapy

Track 7

Neurotoxicity associated with the use of taxanes

Track 8

Advantages of nanoparticle albumin-bound (nab) paclitaxel

Track 9

Sequential endocrine therapy for patients with ER-positive, metastatic disease

Track 10

Incorporation of a loading dose when treating with fulvestrant

Track 11

Use of fulvestrant for premenopausal patients

Track 12

Management of ER-positive, node-negative breast cancer

Track 13

Selection of an endocrine agent in the adjuvant setting

Track 14

Ovarian suppression combined with endocrine therapy

Track 15

Adjuvant trastuzumab for patients with low- or intermediate-risk, HER2-positive tumors

Track 16

Cardiac risks associated with the use of trastuzumab


	Mark D Pegram, MD Associate Professor of Medicine David Geffen School of Medicine at UCLA Director, Women’s Cancer Program UCLA/Jonsson Comprehensive Cancer Center Los Angeles, California
	Click here to download the entire interview

Track 1

Introduction

Track 2

Management of HER2-positive breast cancer in the adjuvant setting

Track 3

Clinical trial comparing anastrozole with or without trastuzumab for patients with early-stage, ER-positive, HER2-positive breast cancer

Track 4

Rationale for combining endocrine therapy with biologic agents

Track 5

Strategy for blocking cross talk between estrogen and HER2 receptors

Track 6

Ongoing clinical trial evaluating fulvestrant with trastuzumab

Track 7

Trastuzumab versus lapatinib versus the combination in the treatment of HER2-positive breast cancer

Track 8

Clinical trial of paclitaxel with or without bevacizumab for patients with metastatic disease

Track 9

Potential role of bevacizumab in the adjuvant setting

Track 10

Mechanism of action of bevacizumab combined with chemotherapy

Track 11

Combining bevacizumab with different chemotherapeutic agents

Track 12

Role of nab paclitaxel in treating breast cancer


	Harold J Burstein, MD, PhD Assistant Professor of Medicine Harvard Medical School Breast Oncology Center Dana-Farber Cancer Institute Boston, Massachusetts
	Click here to download the entire interview

Track 1

Introduction

Track 2

Case discussion: Adjuvant chemotherapy for a 52-year-old woman with early-stage, HER2-negative, node-negative breast cancer

Track 3

Impact of endocrine therapy and chemotherapy on reducing a patient’s recurrence risk in early breast cancer

Track 4

Clinical use of the Oncotype DX assay

Track 5

Use of Oncotype DX in treatment decisions

Track 6

Using the Oncotype DX assay to help identify and treat low-risk, ER-positive, node-negative disease

Track 7

Using the Oncotype DX assay to help identify and treat high-risk, ER-positive, node-negative disease

Track 8

Management of chemotherapy side effects and the advantages of dose-dense AC

Track 9

Duration of chemotherapy-induced amenorrhea and the selection of hormone therapy

Track 10

Issues surrounding the optimal duration of adjuvant treatment with aromatase inhibitors

Track 11

Selection of adjuvant therapy for HER2-positive disease

Track 12

Selection of chemotherapeutic agents in combination with trastuzumab

Track 13

Consideration of trastuzumab without chemotherapy

Track 14

Selection of a taxane in the adjuvant setting

Track 15

Potential advantages of nab paclitaxel

Track 16

Monitoring the side effects of aromatase inhibitors


	Stephen E Jones, MD Director, Breast Cancer Research Charles A Sammons Cancer Center Baylor University Medical Center Dallas, Texas Chair, US Oncology Breast Cancer Research Medical Director US Oncology Research Houston, Texas
	Click here to download the entire interview

Track 1

Introduction

Track 2

Factors in determining the prognosis of ER-positive, node-negative disease

Track 3

Selection of hormone therapy for pre- and postmenopausal patients

Track 4

Options and strategies for the treatment of metastatic disease

Track 5

Selection of a taxane for the treatment of metastatic disease